Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and the United States, has announced the closing of a US$18 million in Series B financing round, to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including Kuragenx, while scaling global manufacturing and expanding operations across the U.S., Japan, and the Middle East.The round was led by Protons Corporate, with participation from Galentic Pharma, marquee investor Ashish Kacholia, Noblevast Advisory and Avinya Fund, Burman Family and others. Bandana Kankani, advisor and investor at Pandorum, had guided the transaction, optimizing the alignment between the investment architecture and company’s value creation.Founded by Tuhin Bhowmick and Arun Chandru, Pandorum’s proprietary platform combines biology, engineering, and computation to develop tunable, regenerative exosome therapies that reprogram pathological tissue states, like inflammation and fibrosis, toward functional recovery.“Just like the Ship of Theseus, the human body is constantly being rebuilt. Pandorum focuses on restoring biological memory, redefining regenerative medicine at its core, “said Dr. Tuhin Bhowmick, Co-Founder and CEO of Pandorum. “Our approach treats tissue health, disease, and degeneration as a navigational challenge within an information-constrained biological landscape,” added Dr. Tuhin. “This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning… Read MoreStartupTalky- Business News, Insights and Stories
Home Uncategorized Pandorum Technologies Raises US$18 Million in Series B to Advance Global Access...
